Immunotherapy in Initial Treatment of Anaplastic Thyroid Cancer: Evaluation of Overall Survival in a National Cancer Database Study
Authors' conclusion
IT was associated with prolonged survival in patients with ATC, although confounding factors, such as the retrospective design of the study, lack of detailed IT drug details, and sequencing of therapy, preclude definitive conclusions on its efficacy.
Study context
- Population
- Patients with newly diagnosed metastatic and nonmetastatic anaplastic thyroid cancer (ATC) treated with surgery, radiation, chemotherapy, or a combination, National Cancer Database (2008–2020)
- Participants
- 3,318 patients
- Exposure
- Immunotherapy vs no immunotherapy (IT)
- ITn = 87
- Outcome
- OS
Methodological detailsNational Cancer Database (2008-2020)
- National Cancer Database (2008-2020)
Main finding
As reported in the abstract
Median OS
P < 0.005
Observational data: associations, not effects.
Further findings
| Outcome | IT | No IT | P value |
|---|---|---|---|
| 5-year OS | 18% (CI 5–36%) | 9% (CI 8–10%) | P < 0.0001 |
5-year overall survival (OS) with trimodality therapy (surgery, IT and radiation), n=23
- 5-year OS with trimodality therapy vs patients who did not
- 35% (CI: 16-55%) vs 9%
Original publication
Immunotherapy in Initial Treatment of Anaplastic Thyroid Cancer: Evaluation of Overall Survival in a National Cancer Database Study. Thyroid. Published 3 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →